Do patients necessarily have to start with an angiotension converting enzyme inhibitor in the treatment of heart failure? Results of the CARMEN (Carvedilol ACE Inhibitor Remodeling Mild CHF Evaluation) study  by Remme, Willem J. et al.
Subspecialty 
162A ABSTRACTS - Cardiac Function and Heart Failure JACC 
Nes Group Non Nes Group P-value 
(i.e. beta blockers), and SP has been prescribed to a broad population of HF patients. 
We sought to define the incidence of HK and RI with SP therapy in HF patients in our 
clinicat practice. 
Methods: We studied clinical data from 926 consecutive patients with HF started on SP 
from 1996 to 2002. We compared baseline characteristics, medications & laboratory data 
at selected time points on 126 randomly selected controls and 67 (7.2%) cases (SP was 
stopped due to HK - >B.OmEqlL or RI - creatinine >= 2.5 mg/dL). Between group compar- 
ison was done using non-parametric Mann-Whitney tests. Multivariate logistic regression 
was performed to Identify independent predictors of HK and RI. Data are expressed as 
mean + s.d., p value. 
Results: Analysis of the study subjects (age 59 f 13, female 37%, ejectlon fraction 0.25 
* 0.13, angiotensin converting enzyme inhibitors 94%, beta blockers 64%) revealed that, 
compared to controls, cases were older (63 f 10 vs 57 * 14, 0.002), had lower New York 
Heart Association class (2.4 * 0.5 vs 2.6 t 0.7, 0.04), had higher baseline serum glucose 
(144 i 72 vs 124 + 63 mg/dL, O.Ol), potassium (4.4 kO.4 vs 4.3 t 0.5 mEq/L, 0.02), and 
creatinine (1.3 * 0.3 vs 1.2 * 0.3 mg/dL, 0.02). and were more likely to be treated with 
beta blockers (96% vs 79%, 0.002) and thiazide diuretics (43% vs 29%, 0.04). Indepen- 
dent predictors of HK included age, beta blocker use, diabetes and baseline potassium 
dosage, while independent predictors of RI included thiazide diuretic use and baseline 
creatinine. 
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Baseline parameters 
Age (years) 56 
Gender-Male 41(72%) 
Systolic pressure (.SP)(mm Hg) 115 
Sodium (mEqlL) 137 
Blood Urea Nitrogen (BUN) 50 
Serum Creatinine (mg/dL) 1.97 
Ejection Fraction 16 
QRS duration 152 
Using ACEI or ARB (%) 93% 
Using Beta Blockers (%) 59% 
Results (admission to discharge) 
Change in BUN -1.9 
Change in Creatinine -0.11 
Change in Weight (pounds) 10.5 
LOS (days) 2.67 
(n=72) 
66 0.07 
36(55%) 0.04 
126 0.011 
137 0.759 
40 0.067 
1.57 0.023 
24 0.023 
130 0.005 
66.5% 0.54 
69% 0.45 
-1.4 0.643 
-0.01 0.636 
11 0.740 
3.79 0.002 
Conclusion: Although the Nes Group was more ill, LOS was significantly shorter for this 
group. In addition use of Nes resulted in no significant change in renal function, same 
decrease in weight in a shorter period of time. Thus, use of Nes as initial therapy may 
allow more rapid discharge of patients without compromising renal function 
1085-72 Discordant Prescription of Guideline-Directed Therapy 
for Heart Failure Between Subspecialties of Cardiology 
Marv N. Walsh, Cynthia D. Adams, The Care Group, LLC, Indianapolis, IN 
Background: The updated ACCIAHA guidelines for management of heart failure (HF) 
clearly describe the mortality and morbidity benefits associated with beta blockers (BB) 
and ACE inhibitors in HF. In spite of wide dissemination of these data, variability in 
adherence likely exists. The purpose of this study was to examine practice patterns 
among cardiologists with regard to prescription of BB and either ACE inhibitors or angio- 
tensin II receptor blockers (ACE) in HF patients (pts). 
Methods: The electronic medical record (EMR) at a large, urban cardiology practice was 
queried to report BB and ACE use in pts with diagnoses of HF or cardiomyopathy. The 
ability of the EMR to select pts by diagnosis, sort by physician, and identify medications, 
enabled examination of variability in prescribing practices. 
Results: 1956 pts with appropriate diagnoses were examined. 57% were prescribed BB; 
75% ACE; and 46% both. The range of BB use among individual physicians was 20. 
94%; ACE 44-93%: and both 14.67%. Comparison between subspecialists is outlined 
below. 
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Conclusion: Wide variation was found in the prescription of BB and ACE in HF pts 
among cardiology subspecialties. HF specialists most closely adhered to guidelines. 
Most notably, BB plus ACE was prescribed in 61% of pts by HF specialists, compared to 
only 3247% by other cardiologists. These data clearly show the need for increased 
awareness of guideline-directed therapy, even among cardiologists. Such feedback may 
enhance appropriate use of proven therapies. 
1085-73 Splronolactone Induced Renal Impairment and 
Hyperkalemia in Patients With Heart Failure: Can We 
Predict These Side Effects? 
Kamala P. Tamirisa, Keith D. Aaronson, Robert J. Cody, Todd M. Koellin$. University of 
Michigan, Ann Arbor, Ml 
Background: Clinical trials evaluating the effects of spironolactone (SP) in heart failure 
(HF) reported that 2% of patients required discontinuation of SP due to hyperkalemia 
(HK) or renal impairment (RI). Medical therapy for HF has evolved since these studies 
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Conclusions: SP induced HK and RI are more common in our clinical experience than 
reported previously. This difference may be partially explained by the frequent use of 
beta blockers to treat HF and concomitant medications and comorbidities. Redoubled 
efforts are necessary to protect patients against these infrequent yet serious side effects 
of SP. 
1085-74 Do Patients Necessarily Have to Start With an 
Angiotension Converting Enzyme Inhibitor In the 
Treatment of Heart Failure? Results of the CARMEN 
(Carvediloi ACE Inhibitor Remodeling Mild CHF 
EvalustloN) Study 
Willem J. Remme, Guenther Riegger, Per Hildebrandt, Michel Komajda, Marco Bobbio, 
Jordi Soler-Soler, Wybren Jaarsma, Stuart Pocock, Lars Ryden, on behalf of the 
CARMEN investigators, Sticares, Rotterdam, The Netherlands 
Background: Treatment guidelines for chronic hean failure (CHF) recommend ACE- 
inhibitor (ACE-I) as first-line treatment and eblcckers are to be added in case patients 
remain symptomatic. This paradigm, based on historical grounds, enforces polyphar- 
macy and prevents an individualized approach to the treatment of CHF. The aims of the 
CARMEN trial were to challenge this paradigm by comparing the effect on cardiac 
remodeling of the ACE-I Enalapril (E) against Carvedilol (C) a combined PI/&- blocker 
with additional a, -receptor blockade and antioxidant properties. 
Methods: CARMEN is a parallel-group, 3.arm, double-dummy, multi-center study con- 
ducted in 13 European countries. Patients were randomized to C&E, C or E treatment, 
uptitrated on C to 25mg (50mg in patients _> 65kg) bid target dose and/or E to 1Omg bid 
target dose, and continued for 16 months. In the C&E treated arm. C was uptitrated first. 
Effects on left ventricular (LV) remodeling were assessed by serial transthoracic 
echocardiography (biplane, Simpson) at baseline, months 6, 12 and 16 at a central core 
laboratory. 
Results: The ITT population included 479 mild (NYHA II = 65%, LV ejection fraction (EF) 
<40%) CHF patients (C&E = 156; C = 161; E = 160), 61% male, mean age 62 years. LV 
end systolic volume index (LVESVI) was reduced by 5.4 ml/m* (p=O.O015), LV end dias- 
tolic volume index by 5.0 ml/m2 (p=O.OOSS) and LVEF increased by 2.3% (p=O.O022) at 
month 16 for the primary comparison favoring C&E versus E. The second primary com- 
parison favored C versus E, although differences were not significant. However, in the 
within-group comparison C significantly reduced LVESVI by 2.6 mVm2 (p=O.O16) corn- 
pared to baseline, whereas no changes were observed in E, and LVESVI decreased by 
6.3 ml/ m2 (p=O.OOOl) in C&E. 
All three arm showed very similar safety profiles and withdrawal rates. 
Conclusion: The CARMEN results confirm the current treatment guidelines and provide 
an immediate mandate for prescribing the combination of ACE-I and C in mild CHF 
patients. However, as C was safely initiated before ACE-I and resulted in reversed LV 
remodeling, one might challenge the historical sequence of ACE-I as first-line therapy 
and start treatment with Carvedilol before ACE-I. 
1085-75 Double Blind, Placebo-Controlled Study of Long-Term 
Intermittent Dobutamine Infusion With Concomitant 
Oral Amiodsrone for End Stage Heart Failure 
Eleftheria Tsagalou, Maria Anastasiou-Nana, George Alexopoulos, John Terrovitis, 
Konstantinos Chalkias, Christos Gialamas, Konstantinos Christodoulou, John Kanakakis, 
John N. Nanas. University of Athens, Athens, Greece 
Background: Agents with positive inotropic affect have consistently been shown to 
increase mortality when administered chronically to patients with congestive heart failure 
(CHF). A non randomized study has showed that long-term intermittent dobutamine infu- 
sion (IDI) combined with oral amiodarone, improves the sumival of patients with end 
stage CHF .The purpose of this randomized double blind study was to evaluate prospec- 
tively the effects of long-term IDI combined with oral amiodarone in patients with CHF, 
refractory to slandard medical treatment. Methods: Thirty patients with decompensated 
CHF refractory to standard treatment were randomized in a double blind manner to 
receive for 6 hours every 14 days intravenous infusion of placebo (Group 1, n=14), or 
dobutamme lOpg/kg/min, (Group 2, n=l6). All patients were treated with oral amio- 
darone, 400mgld, started at least 2 weeks before randomization. Results: There ware 
no differences in baseline clinical, hemodynamic and biochemical characteristics 
between the two groups. The left ventricular ejection fraction was 24 i5 % and 23+6% in 
Group 1 and 2 respectively (~~0.563); mean pulmonary capillary wedge pressure 30*6 
